Anavex Life Sciences Corp (OTCMKTS:AVXL) reported appointment of Dr. Harald Hampel, MA, MD, PhD, MSc, to its Scientific Advisory Board. An internationally distinguished expert on Alzheimer’s disease and linked neurodegenerative diseases, Dr. Hampel designates as AXA Research Fund Chair and Professor at world-famous Marie Curie University as well as Sorbonne Universities’ Pierre located in Paris.
The AXA-UPMC Chair is held within the renowned ‘Institute for Memory and Alzheimer’s Disease’, a reference center for AD and other neurodegenerative diseases. It is also affiliated with a neuroscience institution, named as the ‘Brain and Spine Institute’, and the ‘Pitié-Salpétrière University’ Hospital.
Christopher U. Missling, the President and CEO of Anavex Life, stated that they are thrilled to greet Dr. Hampel in company’s Scientific Advisory Board. Dr. Hampel has performed as many as fifty clinical studies in the past 20 years and is termed as a leading researcher who has worked on advance international programs targeting Alzheimer’s and the development of various imaging and biological biomarkers.
The main objective is to improve the detection process of the disease at preclinical silent stage. It is the time when there is no onset of clinical indications or symptoms. The CEO said that they believe Dr. Hampel’s extensive knowledge of Alzheimer’s disease, his interest and experience in the respective field, and focus on early diagnosis, detection and intervention goes well with the Anavex’s therapeutic approach and offers noteworthy value as they progress investigational drug through the clinic.
The expert comments
Expressing his views on new role Dr. Hampel stated that he is impressed with the company and the its investigational drug ANAVEX 2-73, which showed encouraging interim clinical findings from Phase 2a study targeting Alzheimer’s.
Anavex Life Sciences Corp (OTCMKTS:AVXL) had yet another quiet session as it finished the last trading session with a minor loss of 0.78%. The lack of activity or trading interest on the part of the investors was well reflected in the volume of 1.6 million for the day, lower than the already shrunk daily average of 2 million only. The final closing price of $1.2750 was almost the same with the opening price of $1.29, indicating the indecisive state of the bulls or the bears, unable to trigger any real trending move. The contraction phase in the short term may end soon.